Global practice variation in pharmacologic thromboprophylaxis for general and gynaecological surgery: systematic review

Negar Pourjamal1,2, Lauri I. Lavikainen1, Alex L. E. Halme1, Rufus Cartwright2,3, Kaisa Ahopelto4, Gordon H. Guyatt3,6,7 and Kari A. O. Tikkinen7,8,*

1Faculty of Medicine, University of Helsinki, Helsinki, Finland
2Department of Obstetrics and Gynaecology, London North West Healthcare NHS Trust, London, UK
3Department of Epidemiology & Biostatistics, Imperial College London, London, UK
4Department of Transplantation and Liver Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
5Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada
6Department of Medicine, McMaster University, Hamilton, Canada
7Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
8Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland

*Correspondence to: Kari A. O. Tikkinen, Department of Urology, University of Helsinki and Helsinki University Hospital, Biomedicum 2 B, PO Box 13, 00290 Helsinki, Finland (e-mail: kari.tikkinen@helsinki.fi)

Dear Editor

Venous thromboembolism (VTE) and bleeding are serious complications of surgery. Pharmacological prophylaxis decreases VTE but increases bleeding1. The decision to use thromboprophylaxis requires balancing decreasing VTE versus increased risk of bleeding2. Expert recommendations regarding VTE prophylaxis in surgery vary3, but the extent of practice variation remains uncertain.

We performed comprehensive literature searches in Embase, MEDLINE, Web of Science, and Google Scholar for observational studies with procedure-specific information on VTE and/or bleeding for 16 general abdominal and 22 gynaecological surgery procedures until November 20204 (PROSPERO CRD42021234119) (Supplementary material). Two reviewers independently assessed eligibility and extracted data using standardized, piloted data forms, guided by written instructions. We included surgical procedures that had been investigated in at least five studies, with the majority of participants enrolled from 2000 onwards (Supplementary material). For each study, we extracted data on the proportion of patients receiving pharmacological prophylaxis, and the duration of prophylaxis. For each procedure, we calculated the proportion of discretionary use of pharmacological prophylaxis, and the mean or median duration of prophylaxis.

Of 32,523 potentially relevant titles and abstracts, 4,082 warranted full-text review, of which 50 reports addressing five general and two gynaecological procedures were eligible: laparoscopic cholecystectomy (7 studies), open gastric bypass (7), open groin hernia repair (6), open liver resection (6), open ovarian cancer surgery (9), open radical hysterectomy (5), and laparoscopic sleeve gastrectomy (10) (Figs. S1 and S2 and Table S1). Table S2 presents study characteristics.

All 50 studies reported whether prophylaxis was used; 29 of 46 (63 per cent) studies in which prophylaxis was used, also reported the duration of use.

Studies consistently reported high rates of prophylaxis in open gastric bypass, laparoscopic sleeve gastrectomy, open radical hysterectomy (one exception), and open ovarian cancer surgery (one exception). The duration of pharmacological prophylaxis varied between 4 and 20 days after open gastric bypass, between 1 and 35 days after laparoscopic sleeve gastrectomy, between 4 and 12 days after open radical hysterectomy, and between 7 and 28 days after open ovarian cancer surgery (Fig. 1).

The proportion receiving prophylaxis varied widely in laparoscopic cholecystectomy, open groin hernia repair, and open liver resection. The duration of pharmacological prophylaxis varied between 2 and 3 days after laparoscopic cholecystectomy, between 6 and 27 days after open liver resection, and only one study reported the duration for hernia repair (Fig. 1).

Studies of laparoscopic cholecystectomy, open hernia repair, and open liver resection reported large variation in the use of pharmacological prophylaxis (Fig. 1). Studies in cancer and obesity surgery consistently reported high rates of use of pharmacological prophylaxis, but with substantial variation in the duration of prophylaxis.

Earlier studies have addressed pharmacological prophylaxis in one or more centres1,5, but our study examines variation in practice across studies. The other strengths of this review include a thorough search of contemporary studies, application of explicit eligibility criteria, and standardized piloted data forms for data collection.

This article has limitations. Although we screened many potential studies, only a small proportion proved eligible (1.4 per cent of full
These 50 studies (of which 15 had low risk of bias, 19 had moderate risk, and 16 had high risk of bias; Tables S3 and S4) published between 2000 and 2020 represent seven procedures each with 5–10 studies.

We identified substantial practice variation, within and between countries, in the use of pharmacological prophylaxis in most types of benign surgery, and in the duration of prophylaxis after cancer surgery. Rationalization of practice will require evidence that provides a better understanding of procedure-specific risks of VTE and bleeding as well as creation of procedure-specific, evidence-based guidelines for thromboprophylaxis. Rationalization of current practice would decrease both under- and overuse of thromboprophylaxis improving patient outcomes.

Fig. 1 Proportion (in percentages) of patients with reported use of pharmacological prophylaxis

Depending on the study, the mean or median duration of pharmacological prophylaxis (in days) for those who received any is noted on each bar (if reported in the article).

**Funding**

This study was supported by the Academy of Finland (309387 and 340957), Sigrid Jusélius Foundation and Competitive Research Funding of the Helsinki University Hospital (TYH2019321, TYH2020248, and TYH20222330). The sponsors had no role in the analysis and interpretation of the data or the manuscript preparation, review, or approval.

**Acknowledgements**

The authors would like to thank ROTBIGGS Investigators (Appendix S1) for their efforts in screening titles, abstracts, and/or full texts for eligibility. N.P. and L.I.L. share first authorship.
Disclosure
The authors declare no conflict of interest. R.C. and K.A.O.T. are panel members of the European Society of Anaesthesiology and Intensive Care Task Force for the European Guidelines on Venous Thromboembolism.

Supplementary material
Supplementary material is available at BJS Open online.

Data availability
The corresponding author is the custodian of the data and will provide access to data on request.

References
1. Marcucci M, Etxeandia-Ixobaltzeta I, Yang S, Germini F, Gupta S, Agarwal A et al. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing noncardiac surgery: systematic review and network meta-analysis of randomised trials. BMJ 2022;376:e066785
2. Tikkinen KAO, Guyatt GH. Baseline risks of venous thromboembolism and major bleeding are crucial in decision-making on thromboprophylaxis. Eur Urol 2020;78:369–370
3. Lavikainen LI, Guyatt GH, Lee Y, Couban RJ, Luomaranta AL, Sallinen VJ et al. Systematic reviews of observational studies of Risk of Thrombosis and Bleeding in General and Gynecologic Surgery (ROTBIGGS): introduction and methodology. Syst Rev 2021;10:264
4. Krell RW, Scally CP, Wong SL, Abdelsattar ZM, Birkmeyer NJO, Fegan K, et al. Variation in hospital thromboprophylaxis practices for abdominal cancer surgery. Ann Surg Oncol 2016;23:1431–1439
5. Weiss MJ, Kim Y, Ejaz A, Spolverato G, Haut ER, Hirose K et al. Venous thromboembolic prophylaxis after a hepatic resection: patterns of care among liver surgeons. HPB (Oxford) 2014;16:892–898